Compare DexCom, Inc. (DXCM) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares Core High Dividend ETF — how do they compare? DexCom, Inc. trades at $78.55 (market cap $28.06B), while iShares Core High Dividend ETF trades at $28.25. The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | HDV | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | — |
52-Week High | $89.53 | $28.09 |
52-Week Low | $54.84 | $23.64 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
HDV, the iShares Core High Dividend ETF, trades at $28.20, up 2.03% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent corporate actions include a 1:5 stock split in April 2026 and upcoming dividend payments. The ETF focuses on large-cap value stocks with a defensive tilt, emphasizing high-quality, dividend-paying companies. News coverage highlights its competitive expense ratio and comparisons with peers like SCHD and VYM.
The outlook for HDV is supported by its defensive sector allocation and income focus, appealing in uncertain markets. Risks include concentration in energy and healthcare, which may introduce volatility. Analyst sentiment is mixed, weighing yield against diversification. The ETF suits investors seeking steady dividends with moderate growth, but sector-specific risks require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
